BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, Marrone A, Pafundi PC, Solano A, Lombardi R, Sasso FC, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis 2020;296:40-7. [DOI: 10.1016/j.atherosclerosis.2020.01.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Matboli M, Gadallah SH, Rashed WM, Hasanin AH, Essawy N, Ghanem HM, Eissa S. mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:6770. [PMID: 34202571 DOI: 10.3390/ijms22136770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Hsiao CC, Teng PH, Wu YJ, Shen YW, Mar GY, Wu FZ. Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis. BMC Cardiovasc Disord 2021;21:244. [PMID: 34011282 DOI: 10.1186/s12872-021-02060-z] [Reference Citation Analysis]
3 Nevola R, Acierno C, Pafundi PC, Adinolfi LE. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Med 2021;112:188-200. [PMID: 33205641 DOI: 10.23736/S0026-4806.20.07129-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Rosato V, Ascione A, Nevola R, Fracanzani AL, Piai G, Messina V, Claar E, Coppola C, Fontanella L, Lombardi R, Staiano L, Valente G, Fascione MC, Giorgione C, Mazzocca A, Galiero R, Perillo P, Marrone A, Sasso FC, Adinolfi LE, Rinaldi L. Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. J Viral Hepat 2021. [PMID: 34582610 DOI: 10.1111/jvh.13617] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Matsumori A. Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains. Biomedicines 2022;10:666. [DOI: 10.3390/biomedicines10030666] [Reference Citation Analysis]
6 Torti C, Scaglione V, Cesana BM, Costa C, Marascio N, Schiaroli E, Busti C, Bastianelli S, Mazzitelli M, Trecarichi EM, Francisci D. Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level. Health Sci Rep 2021;4:e273. [PMID: 33969232 DOI: 10.1002/hsr2.273] [Reference Citation Analysis]
7 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, Zeng YH, Huang SP, Hsu YC, Wu SS, Siao FY, Yen HH. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. J Clin Med 2021;10:5236. [PMID: 34830518 DOI: 10.3390/jcm10225236] [Reference Citation Analysis]
9 Rojano-Toimil A, Rivera-Esteban J, Manzano-Nuñez R, Bañares J, Martinez Selva D, Gabriel-Medina P, Ferrer R, Pericàs JM, Ciudin A. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. J Clin Med 2022;11:3286. [PMID: 35743358 DOI: 10.3390/jcm11123286] [Reference Citation Analysis]
10 Rosato V, Kondili LA, Nevola R, Perillo P, Mastrocinque D, Aghemo A, Claar E. Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. Viruses 2022;14:1096. [DOI: 10.3390/v14051096] [Reference Citation Analysis]
11 Rajewski P, Zarębska-Michaluk D, Janczewska E, Gietka A, Mazur W, Tudrujek-Zdunek M, Tomasiewicz K, Belica-Wdowik T, Baka-Ćwierz B, Dybowska D, Halota W, Lorenc B, Sitko M, Garlicki A, Berak H, Horban A, Orłowska I, Simon K, Socha Ł, Wawrzynowicz-Syczewska M, Jaroszewicz J, Deroń Z, Czauż-Andrzejuk A, Citko J, Krygier R, Piekarska A, Laurans Ł, Dobracki W, Białkowska J, Tronina O, Wietlicka-Piszcz M, Pawłowska M, Flisiak R. HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study. J Clin Med 2022;11:379. [PMID: 35054072 DOI: 10.3390/jcm11020379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Boonchai P, Kositamongkol C, Jitrukthai S, Phothirat S, Mepramoon E, Nimitpunya P, Srivanichakorn W, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Tinmanee R, Sayabovorn N, Charatcharoenwitthaya P, Phisalprapa P. Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. J Clin Med 2022;11:2445. [PMID: 35566571 DOI: 10.3390/jcm11092445] [Reference Citation Analysis]
13 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
14 Nevola R, Rinaldi L, Zeni L, Romano C, Marrone A, Galiero R, Pafundi PC, Acierno C, Vetrano E, Adinolfi LE. Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Rev Gastroenterol Hepatol 2021;15:643-56. [PMID: 33445990 DOI: 10.1080/17474124.2021.1877136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhang C, Liu S, Yang M. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Front Endocrinol (Lausanne) 2021;12:808526. [PMID: 35002979 DOI: 10.3389/fendo.2021.808526] [Reference Citation Analysis]
16 Scelza G, Amato A, Pagano AM, Matteis G, Caruso R, Scelza A, Sisalli L, Biasi S, Marigliano F, Gagliardi M, Martina S, Iandolo A. Effect of hepatitis C antiviral therapy on oral lichen planus and hyposalivation in inmates. Ann Gastroenterol 2022;35:74-9. [PMID: 34987292 DOI: 10.20524/aog.2021.0672] [Reference Citation Analysis]
17 George ES, Georgousopoulou EN, Mellor DD, Chrysohoou C, Pitsavos C, Panagiotakos DB. Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012). Nutrients 2022;14:2367. [PMID: 35745097 DOI: 10.3390/nu14122367] [Reference Citation Analysis]
18 Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC. Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00019] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kondili LA, Aghemo A, Andreoni M, Galli M, Rossi A, Babudieri S, Nava F, Leonardi C, Mennini FS, Gardini I, Russo FP. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. Dig Liver Dis 2021:S1590-8658(21)00142-0. [PMID: 33926816 DOI: 10.1016/j.dld.2021.03.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
20 Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Reference Citation Analysis]
21 Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, Pisano G, Fatta E, Sigon G, Iuculano F, Crapanzano L, Gibilaro G, Francione P, Craxì A, Fargion S, Fracanzani AL. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis 2020:S1590-8658(20)30997-X. [PMID: 33214063 DOI: 10.1016/j.dld.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Guagnano MT, D'ardes D, Ilaria R, Santilli F, Schiavone C, Bucci M, Cipollone F. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. JCM 2022;11:2759. [DOI: 10.3390/jcm11102759] [Reference Citation Analysis]
23 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
24 Amzolini AM, Forțofoiu M, Alhija AB, Vladu IM, Clenciu D, Mitrea A, Forțofoiu M, Matei D, Diaconu M, Tudor MS, Micu ES. Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome. JCM 2022;11:3043. [DOI: 10.3390/jcm11113043] [Reference Citation Analysis]
25 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Reference Citation Analysis]
26 Di Stasio D, Lucchese A, Romano A, Elio Adinolfi L, Serpico R, Marrone A. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. Clin Oral Investig 2022. [PMID: 35477818 DOI: 10.1007/s00784-022-04507-9] [Reference Citation Analysis]
27 Lonardo A, Mantovani A. Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. Nutr Metab Cardiovasc Dis 2021;31:2354-7. [PMID: 34154889 DOI: 10.1016/j.numecd.2021.05.019] [Reference Citation Analysis]
28 Ciardullo S, Mantovani A, Ciaccio A, Carbone M, Invernizzi P, Perseghin G. Hepatitis C virus infection and diabetes: A complex bidirectional relationship. Diabetes Research and Clinical Practice 2022;187:109870. [DOI: 10.1016/j.diabres.2022.109870] [Reference Citation Analysis]
29 Valenti L, Pelusi S, Aghemo A, Gritti S, Pasulo L, Bianco C, Iegri C, Cologni G, Degasperi E, D'Ambrosio R, Del Poggio P, Soria A, Puoti M, Carderi I, Pigozzi MG, Carriero C, Spinetti A, Zuccaro V, Memoli M, Giorgini A, Viganò M, Rumi MG, Re T, Spinelli O, Colombo MC, Quirino T, Menzaghi B, Lorini G, Pan A, D'Arminio Monforte A, Buscarini E, Autolitano A, Bonfanti P, Terreni N, Aimo G, Mendeni M, Prati D, Lampertico P, Colombo M, Fagiuoli S; NAVIGATORE-Lombardia Network. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. Hepatol Commun 2021. [PMID: 34811949 DOI: 10.1002/hep4.1851] [Reference Citation Analysis]
30 Cheng C, Chu C, Chen H, Lin I, Wu C, Lee Y, Bair M. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients. Front Endocrinol 2022;12:799382. [DOI: 10.3389/fendo.2021.799382] [Reference Citation Analysis]
31 Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021;9:1491. [PMID: 34680608 DOI: 10.3390/biomedicines9101491] [Reference Citation Analysis]
32 Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [DOI: 10.4254/wjh.v14.i6.1053] [Reference Citation Analysis]
33 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
34 Kosmalski M, Ziółkowska S, Czarny P, Szemraj J, Pietras T. The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. J Clin Med 2022;11:1375. [PMID: 35268466 DOI: 10.3390/jcm11051375] [Reference Citation Analysis]
35 Nakashima A, Kato K, Ohkido I, Yokoo T. Role and Treatment of Insulin Resistance in Patients with Chronic Kidney Disease: A Review. Nutrients 2021;13:4349. [PMID: 34959901 DOI: 10.3390/nu13124349] [Reference Citation Analysis]
36 Adinolfi LE, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, Rinaldi L, Calvaruso V, Pafundi PC, Lombardi R, Staiano L, Di Marco V, Solano A, Marrone A, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A, Sasso FC. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study. Diabetes Obes Metab 2020;22:2408-16. [DOI: 10.1111/dom.14168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
37 Salomone F, Petta S, Micek A, Pipitone RM, Distefano A, Castruccio Castracani C, Rini F, Di Rosa M, Gardi C, Calvaruso V, Di Marco V, Li Volti G, Grimaudo S, Craxì A. Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. Liver Int 2020;40:2820-7. [PMID: 32666695 DOI: 10.1111/liv.14608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
38 Elsharkawy A, Samir R, El-Kassas M. Fibrosis regression following hepatitis C antiviral therapy. World J Hepatol 2022; 14(6): 1120-1130 [DOI: 10.4254/wjh.v14.i6.1120] [Reference Citation Analysis]
39 Gitto S, De Maria N, Marzi L, Magistri P, Falcini M, Vitale G, Olivieri T, Guerrini GP, Serra V, Forte P, Carrai P, De Simone P, Mega A, Zoller H, Piai G, Schepis F, Marocchi M, Villa E, Marra F, Andreone P, Di Benedetto F; other members of MEDITRA research group. Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study. Eur J Intern Med 2020;79:70-5. [PMID: 32616342 DOI: 10.1016/j.ejim.2020.05.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
40 Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, Rinaldi L, Salvatore T, Marfella R, Sardu C, Moscarella E, Gragnano F, Calabrò P, Sasso FC. Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Res Clin Pract 2021;178:108959. [PMID: 34280467 DOI: 10.1016/j.diabres.2021.108959] [Reference Citation Analysis]
41 Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, Tonizzo M, Gitto S, Andreone P, Gattei V. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Viruses 2021;13:2249. [PMID: 34835054 DOI: 10.3390/v13112249] [Reference Citation Analysis]